267 related articles for article (PubMed ID: 27870562)
1. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
Visvanathan K; Fackler MS; Zhang Z; Lopez-Bujanda ZA; Jeter SC; Sokoll LJ; Garrett-Mayer E; Cope LM; Umbricht CB; Euhus DM; Forero A; Storniolo AM; Nanda R; Lin NU; Carey LA; Ingle JN; Sukumar S; Wolff AC
J Clin Oncol; 2017 Mar; 35(7):751-758. PubMed ID: 27870562
[TBL] [Abstract][Full Text] [Related]
2. Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.
Connolly RM; Fackler MJ; Zhang Z; Zhou XC; Goetz MP; Boughey JC; Walsh B; Carpenter JT; Storniolo AM; Watkins SP; Gabrielson EW; Stearns V; Sukumar S
Breast Cancer Res Treat; 2018 Jan; 167(1):107-116. PubMed ID: 28918548
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
4. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.
Panagopoulou M; Karaglani M; Balgkouranidou I; Biziota E; Koukaki T; Karamitrousis E; Nena E; Tsamardinos I; Kolios G; Lianidou E; Kakolyris S; Chatzaki E
Oncogene; 2019 May; 38(18):3387-3401. PubMed ID: 30643192
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.
Visvanathan K; Cope L; Fackler MJ; Considine M; Sokoll L; Carey LA; Forero-Torres A; Ingle JN; Lin NU; Nanda R; Storniolo AM; Tulac S; Venkatesan N; Wu NC; Marla S; Campbell S; Bates M; Umbricht CB; Wolff AC; Sukumar S
Clin Cancer Res; 2023 Feb; 29(4):784-790. PubMed ID: 36534524
[TBL] [Abstract][Full Text] [Related]
6. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.
Fackler MJ; Lopez Bujanda Z; Umbricht C; Teo WW; Cho S; Zhang Z; Visvanathan K; Jeter S; Argani P; Wang C; Lyman JP; de Brot M; Ingle JN; Boughey J; McGuire K; King TA; Carey LA; Cope L; Wolff AC; Sukumar S
Cancer Res; 2014 Apr; 74(8):2160-70. PubMed ID: 24737128
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
8. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
9. DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.
Gampenrieder SP; Rinnerthaler G; Hackl H; Pulverer W; Weinhaeusel A; Ilic S; Hufnagl C; Hauser-Kronberger C; Egle A; Risch A; Greil R
Theranostics; 2018; 8(8):2278-2288. PubMed ID: 29721079
[No Abstract] [Full Text] [Related]
10. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.
Wallwiener M; Riethdorf S; Hartkopf AD; Modugno C; Nees J; Madhavan D; Sprick MR; Schott S; Domschke C; Baccelli I; Schönfisch B; Burwinkel B; Marmé F; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2014 Jul; 14():512. PubMed ID: 25015676
[TBL] [Abstract][Full Text] [Related]
11. Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.
Gunnarsdottir FB; Bendahl PO; Johansson A; Benfeitas R; Rydén L; Bergenfelz C; Larsson AM
Breast Cancer Res; 2023 Mar; 25(1):29. PubMed ID: 36945037
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
[TBL] [Abstract][Full Text] [Related]
13. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.
Shan M; Yin H; Li J; Li X; Wang D; Su Y; Niu M; Zhong Z; Wang J; Zhang X; Kang W; Pang D
Oncotarget; 2016 Apr; 7(14):18485-94. PubMed ID: 26918343
[TBL] [Abstract][Full Text] [Related]
14. Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk.
Stearns V; Fackler MJ; Hafeez S; Bujanda ZL; Chatterton RT; Jacobs LK; Khouri NF; Ivancic D; Kenney K; Shehata C; Jeter SC; Wolfman JA; Zalles CM; Huang P; Khan SA; Sukumar S
Cancer Prev Res (Phila); 2016 Aug; 9(8):673-682. PubMed ID: 27261491
[TBL] [Abstract][Full Text] [Related]
15. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating tumor cells in breast cancer patients: prognostic predictive role.
Turker I; Uyeturk U; Sonmez OU; Oksuzoglu B; Helvaci K; Arslan UY; Budakoglu B; Alkis N; Aksoy S; Zengin N
Asian Pac J Cancer Prev; 2013; 14(3):1601-7. PubMed ID: 23679243
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
Cristofanilli M; Hayes DF; Budd GT; Ellis MJ; Stopeck A; Reuben JM; Doyle GV; Matera J; Allard WJ; Miller MC; Fritsche HA; Hortobagyi GN; Terstappen LW
J Clin Oncol; 2005 Mar; 23(7):1420-30. PubMed ID: 15735118
[TBL] [Abstract][Full Text] [Related]
19. A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study.
Gagno S; D'Andrea MR; Mansutti M; Zanusso C; Puglisi F; Dreussi E; Montico M; Biason P; Cecchin E; Iacono D; Russo S; Cinausero M; Saracchini S; Gasparini G; Sartori D; Bari M; Collovà E; Meo R; Merkabaoui G; Spagnoletti I; Pellegrino A; Gianni L; Sandri P; Cretella E; Vattemi E; Rocca A; Serra P; Fabbri MA; Benedetti G; Foghini L; Medici M; Basso U; Amoroso V; Riccardi F; Baldelli AM; Clerico M; Bonura S; Saggia C; Innocenti F; Toffoli G
Clin Breast Cancer; 2019 Apr; 19(2):137-145.e4. PubMed ID: 30584056
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
